TSE:GUD Knight Therapeutics (GUD) Stock Price, News & Analysis C$9.80 0.00 (0.00%) As of 07/13/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesBuy This Stock About Knight Therapeutics Stock (TSE:GUD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Knight Therapeutics alerts:Sign Up Key Stats Today's RangeC$9.77▼C$9.9050-Day RangeC$7.51▼C$10.0752-Week RangeC$5.66▼C$10.17Volume74,352 shsAverage Volume99,645 shsMarket CapitalizationC$962.15 millionP/E Ratio163.33Dividend YieldN/APrice TargetC$9.50Consensus RatingBuy Company Overview Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca. Read More Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GUD Stock News HeadlinesKnight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comKnight to Present at the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | markets.businessinsider.comGates. Google. The Pentagon.Bill Gates wrote a $100 million check. Google signed a 15-year contract. The Pentagon named it their top energy priority. All three are backing the same company - and the same energy source that holds 140 times global electricity demand. Last year a drilling crew cracked through three miles of solid rock in 16 days - the government had projected 64. On August 18th, Washington is handing this technology a tax credit advantage that solar and wind no longer receive. | Behind the Markets (Ad)TSX Value Picks Knight Therapeutics And 2 Other Stocks Estimated Below Intrinsic ValueMarch 25, 2026 | uk.finance.yahoo.comKnight Therapeutics advances chronic GvHD expansion strategyFebruary 27, 2026 | finance.yahoo.com3 TSX Growth Companies With Insider Ownership As High As 27%January 28, 2026 | finance.yahoo.comProfound Medical Regains Exclusive Distribution Rights for TULSA-PRO(R) in Canada from KnightNovember 12, 2025 | barrons.comKnight Therapeutics Secures US$100 Million Credit Facility to Boost GrowthOctober 31, 2025 | msn.comSee More Headlines GUD Stock Analysis - Frequently Asked Questions How have GUD shares performed this year? Knight Therapeutics' stock was trading at C$6.05 at the beginning of 2026. Since then, GUD stock has increased by 62.0% and is now trading at C$9.80. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) issued its quarterly earnings data on Thursday, May, 7th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $147.59 million for the quarter. Knight Therapeutics had a net margin of 1.10% and a trailing twelve-month return on equity of 0.73%. Read the conference call transcript. How do I buy shares of Knight Therapeutics? Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include ARC Resources (ARX), Cenovus Energy (CVE), Enbridge (ENB), Whitecap Resources (WCP), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG) and Suncor Energy (SU). Company Calendar Last Earnings5/07/2026Today7/13/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:GUD CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees725Year FoundedN/APrice Target and Rating Average Price Target for Knight TherapeuticsC$9.50 High Price TargetC$9.50 Low Price TargetC$9.50 Potential Upside/Downside-3.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)C$0.06 Trailing P/E Ratio163.33 Forward P/E Ratio97.08 P/E Growth-1013.5Net Income-C$30.73 million Net Margins1.10% Pretax MarginN/A Return on Equity0.73% Return on Assets0.51% Debt Debt-to-Equity Ratio8.86 Current Ratio2.32 Quick Ratio1.79 Sales & Book Value Annual SalesC$510.45 million Price / Sales1.88 Cash FlowC$2.55 per share Price / Cash Flow3.85 Book ValueC$8.00 per share Price / Book1.23Miscellaneous Outstanding Shares98,179,000Free FloatN/AMarket CapC$962.15 million OptionableNot Optionable Beta-0.21 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (TSE:GUD) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
